Oral nanoparticle-encapsulated enzyme replacement therapy for mucopolysaccharidosis type I (MPS-I): a proof of concept study.

Scientists have developed a new way to treat a rare disease called MPS-I by putting the necessary enzyme into tiny fat bubbles (nanoparticles). Instead of painful weekly intravenous infusions, this could be taken orally. This method can reach parts of the body like the brain and bones that current treatments struggle to access.

The barriers to systemic enzyme delivery

Mucopolysaccharidosis type I (MPS-I) is a multisystemic lysosomal storage disease (LSD). In these conditions, a deficiency in the enzyme alpha-L-iduronidase causes glycosaminoglycans (GAGs)—long chains of sugar molecules—to accumulate within lysosomes. Lysosomes are the cell's recycling centers. Think of a lysosome as a cellular waste disposal unit. When the enzyme is missing, the trash piles up and eventually chokes the cell.

Current standard-of-care relies heavily on enzyme replacement therapy (ERT). This involves weekly intravenous infusions of recombinant laronidase. While this helps manage some symptoms, the authors note that ERT faces two massive physical hurdles. First, the enzyme cannot easily cross the blood-brain barrier (a selective semipermeable border that prevents harmful substances from entering the brain). This leaves the central nervous system vulnerable to neurocognitive decline. Second, the enzyme struggles to reach poorly vascularized tissues (areas with low blood vessel density), such as bone. GAG accumulation in these areas causes severe skeletal deformities. Consequently, patients face a high treatment burden and incomplete protection of critical organs.

Protecting cargo within lipid carriers

To bypass these physiological roadblocks, the researchers propose a delivery vehicle: nanostructured lipid carriers (NLCs). These are microscopic fatty droplets designed to shield sensitive biological cargo from the harsh environment of the digestive tract. The authors utilized a "fast double-emulsification" method to build these carriers. They created a water-in-oil-in-water (W/O/W) architecture.

The mechanism functions in three distinct stages. First, the laronidase enzyme is incorporated into a lipid mixture to form a primary emulsion. Here, it is protected within a gel core. Second, this is processed into pegylated nanoparticles. These are particles coated with polyethylene glycol to help them evade immune detection. They are wrapped in a lipid shell. Third, to ensure the enzyme survives the stomach's acidity, the authors applied an enteric coating. They used EUDRAGIT L100-55 via spray drying. This coating acts like a protective capsule. It only dissolves once the particles reach the more neutral environment of the intestines. This prevents premature degradation of the enzyme.

Restoring metabolic and structural homeostasis

The study provides multi-scale evidence that this oral approach can replicate the efficacy of traditional IV delivery. In patient-derived fibroblasts (specialized cells that support tissue structure), the authors report that NLC treatment significantly restored enzyme activity. It also reduced the accumulation of heparan sulfate (HS), a specific type of GAG. Interestingly, the paper finds that the NLC formulation showed greater potential to normalize GAG levels than standard ERT. This is likely because the oral route allows for more frequent dosing.

The most striking evidence comes from proteomic analysis. This technique looks at the entire landscape of proteins within a cell. The authors report that NLC treatment helped normalize protein expression across several critical pathways. These include glycolysis (the breakdown of glucose to produce energy), the cytoskeleton (the cell's structural framework), and lysosomal trafficking. This is visualized in the heatmap .

The heatmap demonstrates how NLC treatment shifts protein expression profiles toward those of healthy controls.

Moving to animal models, the researchers demonstrated that orally administered NLCs achieve widespread biodistribution (the way a drug spreads throughout the body). Using fluorescent labeling, the study shows that the particles and their enzyme cargo reach virtually all disease-affected tissues in MPS-I knockout mice. This includes the brain and bone. The authors report significant enzymatic activity in these target tissues 24 hours after a single oral dose.

Assessing the limits of lipid delivery

Despite these promising results, the transition to clinical reality faces specific technical challenges. The authors identify a notable instance of lipotoxicity in human intestinal fibroblast (HIF) cells. Lipotoxicity occurs when the accumulation of lipids causes cellular stress. This was observed at a concentration of 300 µg/mL. This suggests a narrow therapeutic window. The dosage must be high enough to be effective but low enough to avoid damaging the intestinal lining.

Furthermore, the paper notes that the transport of NLCs across the intestinal epithelium appears to be receptor-mediated. This means the transport depends on specific proteins on the cell surface. This process appears potentially slower than the transport of free enzymes. The authors observe that NLCs tend to be internalized and retained within the epithelial cells. They are not always efficiently moved through them (transcytosed) to the rest of the body. Finally, a significant discrepancy was observed between human and mouse cells. The enzyme activity in human fibroblasts was nearly five times higher than in mouse fibroblasts under identical conditions. This makes translating mouse biodistribution data to human clinical outcomes a complex task.

A new route for enzyme replacement

Is this ready for the clinic? Not yet, but the trajectory is clear. The study successfully demonstrates that an oral, nanoparticle-encapsulated enzyme can penetrate the body's most guarded compartments, including the brain. By solving the "access" problem that plagues current IV-based ERT, the researchers have provided a compelling blueprint for treating other lysosomal storage diseases.

If the scalability and toxicity profiles can be managed in larger mammalian models, this technology could fundamentally change the patient experience. It could move patients from a lifetime of hospital-based infusions to a manageable oral regimen.